|
86 Companies |
|
134 Products |
|
134 Products |
|
85 Mechanisms of Action |
|
5 Trials |
|
1881 News |
|
| «12345678910111213...3738» |
- | Kuvan (sapropterin) / Merck (MSD), BioMarin, Daiichi Sankyo
Trial completion, Enrollment change: Kuvan in People With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Sep 13, 2017
P1/2, N=27, Completed, Sponsor: New York State Psychiatric Institute
Suspended --> Completed | N=60 --> 27
- | Trial completion, Enrollment change: Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=21, Completed, Sponsor: Lawson Health Research Institute
Suspended --> Completed | N=60 --> 27 Active, not recruiting --> Completed | N=30 --> 21
- | L-threonic acid magnesium salt (NRCT-101) / Neurocentria
Trial completion, Phase classification, Trial primary completion date: Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia (clinicaltrials.gov) - Sep 5, 2017
P2, N=60, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed | N=30 --> 21 Recruiting --> Completed | Phase classification: P4 --> P2 | Trial primary completion date: Mar 2018 --> Aug 2017
- | metformin / Generic mfg.
Enrollment change, Trial initiation date: Metformin for Weight Loss in Schizophrenia (clinicaltrials.gov) - Sep 1, 2017
P=N/A, N=12, Terminated, Sponsor: Nathan Kline Institute for Psychiatric Research
Recruiting --> Completed | Phase classification: P4 --> P2 | Trial primary completion date: Mar 2018 --> Aug 2017 N=15 --> 12 | Initiation date: May 2000 --> May 2008
- | Trial primary completion date: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Aug 31, 2017
P4, N=200, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=15 --> 12 | Initiation date: May 2000 --> May 2008 Trial primary completion date: Jun 2017 --> Mar 2017
- ||| Clinical protocol, Trial completion, Trial primary completion date: Psychosis-Associated Neuroinflammation in Schizophrenia (clinicaltrials.gov) - Aug 31, 2017
P=N/A, N=106, Completed, Sponsor: Universiteit Antwerpen
Trial primary completion date: Jun 2017 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Feb 2017
- ||| Trial completion, Trial primary completion date: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=200, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Feb 2017 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2016
- | isradipine / Generic mfg.
Trial primary completion date: Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=36, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2016 Trial primary completion date: Jul 2017 --> Dec 2017
- | Enrollment closed, Trial primary completion date: Exercise and Cognitive Training (clinicaltrials.gov) - Aug 10, 2017
P=N/A, N=30, Active, not recruiting, Sponsor: Boston University Charles River Campus
Trial primary completion date: Jul 2017 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Oct 2017
- | Trial completion: tDCS to Enhance Cognitive Training in Schizophrenia (clinicaltrials.gov) - Aug 8, 2017
P1/2, N=52, Completed, Sponsor: The University of New South Wales
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Oct 2017 Recruiting --> Completed
- ||| Clinical data, Trial completion, Trial initiation date, Trial primary completion date: Early Medication Discontinuation and Long-term Clinical Outcome in FEP (clinicaltrials.gov) - Aug 7, 2017
P=N/A, N=178, Completed, Sponsor: Professor Eric Y.H. Chen
Recruiting --> Completed Recruiting --> Completed | Initiation date: Jul 2013 --> Nov 2013 | Trial primary completion date: Mar 2015 --> Dec 2014
- Enrollment change: First Time in Human Study With GSK1018921 (clinicaltrials.gov) - Aug 4, 2017
P1, N=27, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Initiation date: Jul 2013 --> Nov 2013 | Trial primary completion date: Mar 2015 --> Dec 2014 N=54 --> 27
- | Clinical data, Trial suspension: Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=264, Suspended, Sponsor: Northwell Health
N=54 --> 27 Recruiting --> Suspended
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Jul 26, 2017
P=N/A, N=450, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Suspended Enrolling by invitation --> Completed
- | Trial completion, Phase classification, Enrollment change, Trial primary completion date: Cognitive Skills Training Using Computer for Patients With Severe Mental Illness (clinicaltrials.gov) - Jul 21, 2017
P4, N=448, Completed, Sponsor: Nathan Kline Institute for Psychiatric Research
Enrolling by invitation --> Completed Recruiting --> Completed | Phase classification: P2/3 --> P4 | N=200 --> 448 | Trial primary completion date: Dec 2012 --> Dec 2016
- |||| Nuplazid (pimavanserin) / Acadia Pharma
Trial completion: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Jul 18, 2017
P2, N=181, Completed, Sponsor: ACADIA Pharmaceuticals Inc.
Recruiting --> Completed | Phase classification: P2/3 --> P4 | N=200 --> 448 | Trial primary completion date: Dec 2012 --> Dec 2016 Active, not recruiting --> Completed
- | Phase classification: Predictors of Treatment Outcome for Smokers With and Without Schizophrenia (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=203, Completed, Sponsor: Rutgers, The State University of New Jersey
Active, not recruiting --> Completed Phase classification: P1 --> P=N/A
- | Trial completion: Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=365, Completed, Sponsor: University Hospital of North Norway
Phase classification: P1 --> P=N/A Recruiting --> Completed
- | Trial primary completion date: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) - Jul 7, 2017
P1/2, N=18, Terminated, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed Trial primary completion date: Jul 2017 --> Jun 2016
- preladenant (SCH 420814) / Merck (MSD)
Phase classification: Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) (clinicaltrials.gov) - Jul 2, 2017
P2a, N=11, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jul 2017 --> Jun 2016 Phase classification: P2 --> P2a
- | Trial completion: The Role of Norepinephrine in Emotional Processing (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=216, Completed, Sponsor: National Institute of Mental Health (NIMH)
Phase classification: P2 --> P2a Recruiting --> Completed
- | Trial completion: Timing of Voluntary Movement in Patients With Schizophrenia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=42, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Neuropsychological Evaluation of Psychiatric and Neurological Patients (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=4300, Completed, Sponsor: National Institute of Mental Health (NIMH)
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=949, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=112, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders (clinicaltrials.gov) - Jun 28, 2017
P2, N=2, Completed, Sponsor: Mclean Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date, Patient reported outcomes: CIAS PRO: Schizophrenia Cognition Scale Development (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=102, Completed, Sponsor: New England Research Institutes
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jul 2016
- | Trial completion, Trial primary completion date: Effects of Systematic Patient Feedback on Therapy Outcome (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=170, Completed, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017
- | eszopiclone / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Effects of Eszopiclone on Sleep and Memory in Schizophrenia (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=59, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | Trial primary completion date: Jun 2018 --> Jun 2017 Recruiting --> Completed | N=80 --> 59 | Trial primary completion date: Jun 2015 --> Dec 2015
- | metformin / Generic mfg.
Trial primary completion date: Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (clinicaltrials.gov) - Jun 14, 2017
P4, N=24, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Completed | N=80 --> 59 | Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Jun 2017 --> Dec 2017
- | olanzapine / Generic mfg., sertraline / Generic mfg.
Enrollment closed, Enrollment change: STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) - Jun 9, 2017
P4, N=269, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Jun 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=392 --> 269
- ||||| ziprasidone / Generic mfg.
Enrollment change: High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms (clinicaltrials.gov) - Jun 8, 2017
P3, N=131, Completed, Sponsor: Donald C. Goff, MD
Recruiting --> Active, not recruiting | N=392 --> 269 N=80 --> 131
- | acetylcysteine oral / Generic mfg.
Phase classification: NACPSY: N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis (clinicaltrials.gov) - Jun 7, 2017
P2, N=20, Completed, Sponsor: Beth Israel Deaconess Medical Center
N=80 --> 131 Phase classification: P4 --> P2
- ||||| Nuplazid (pimavanserin) / Acadia Pharma
Enrollment change: A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis (clinicaltrials.gov) - May 17, 2017
P3, N=298, Completed, Sponsor: ACADIA Pharmaceuticals Inc.
Phase classification: P4 --> P2 N=240 --> 298
- | Trial completion, Trial primary completion date: APUS e-Cigs: Electronic Cigarettes in Smokers With Mental Illness (clinicaltrials.gov) - May 16, 2017
P=N/A, N=50, Completed, Sponsor: King's College London
N=240 --> 298 Not yet recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2017
- | Phase classification: Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation (clinicaltrials.gov) - May 15, 2017
P=N/A, N=144, Completed, Sponsor: Uni Research
Not yet recruiting --> Completed | Trial primary completion date: Jan 2016 --> May 2017 Phase classification: P3 --> P=N/A
- | clozapine / Generic mfg.
Trial completion: Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine (clinicaltrials.gov) - May 12, 2017
P=N/A, N=76, Completed, Sponsor: Delwyn D. Miller
Phase classification: P3 --> P=N/A Recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Healthy Bodies, Healthy Kids (clinicaltrials.gov) - May 12, 2017
P=N/A, N=50, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Recruiting --> Completed | N=126 --> 50 | Trial primary completion date: Dec 2016 --> Mar 2017
- | Trial completion: RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) (clinicaltrials.gov) - May 10, 2017
P=N/A, N=166, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Recruiting --> Completed | N=126 --> 50 | Trial primary completion date: Dec 2016 --> Mar 2017 Active, not recruiting --> Completed
- | Trial primary completion date: SPA: A System for Preference Assessment in Mental Health (clinicaltrials.gov) - May 2, 2017
P=N/A, N=90, Recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jul 2017
- | Trial completion, Enrollment change: Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=56, Completed, Sponsor: Sykehuset Innlandet HF
Trial primary completion date: Jan 2017 --> Jul 2017 Enrolling by invitation --> Completed | N=91 --> 56
- | clonidine / Generic mfg., dronabinol oral / Generic mfg.
Trial primary completion date: Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia (clinicaltrials.gov) - Apr 27, 2017
P2/3, N=18, Recruiting, Sponsor: Mclean Hospital
Enrolling by invitation --> Completed | N=91 --> 56 Trial primary completion date: Mar 2017 --> Aug 2017
- | Trial primary completion date: NET in Iranian Women Suffering From Post Traumatic Stress Symptoms (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=34, Completed, Sponsor: University of Konstanz
Trial primary completion date: Mar 2017 --> Aug 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- | amisulpride / Generic mfg.
Enrollment change, Trial termination: Optimisation of Antipsychotic Drug Use in Older People (clinicaltrials.gov) - Apr 19, 2017
P4, N=64, Terminated, Sponsor: Institute of Psychiatry, London
Trial primary completion date: Dec 2014 --> Dec 2015 N=120 --> 64 | Recruiting --> Terminated; Failure to recruit people with very late onset schizophrenia like psychosis
- | clozapine / Generic mfg.
Trial completion: Vitamin D for Schizophrenia (clinicaltrials.gov) - Apr 13, 2017
P=N/A, N=47, Completed, Sponsor: Geha Mental Health Center
N=120 --> 64 | Recruiting --> Terminated; Failure to recruit people with very late onset schizophrenia like psychosis Active, not recruiting --> Completed
- | Trial completion: Adaptive Treatment for Adolescent Cannabis Use Disorders (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=172, Completed, Sponsor: UConn Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: Measuring Time Windows in Patients With Schizophrenia and Healthy Controls (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=228, Recruiting, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- | Trial primary completion date: Social Cognition Training in Schizophrenia (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=25, Recruiting, Sponsor: Oslo University Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- | Phase classification, HEOR: Quality of Life and Mental Health in Children and Adolescents (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=2342, Completed, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Jun 2017 --> Jan 2018 Phase classification: P2/3 --> P=N/A
- | Phase classification: Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=33, Completed, Sponsor: Norwegian University of Science and Technology
Phase classification: P2/3 --> P=N/A Phase classification: P2 --> P=N/A